ArticleResearch (Washington, D.C.)2025
Integrated Single-Step Terahertz Metasensing for Simultaneous Detection Based on Exosomal Membrane Proteins Enables Pathological Typing of Gastric Cancer.
Article in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Immunomagnetic-MXene Bifunctional Probes for Ultrasensitive and Specific Terahertz Metasensing of Tumor-Derived Exosomes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Controllable Cascade Aggregation Ion Programmed Nanomachines and Simple Isolation Enable Tumor-Derived Small Extracellular Vesicles Detection for Enhanced Breast Cancer Assessment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Extracellular vesicles in Graves' disease and Graves' orbitopathy: immunoregulatory mechanisms, biomarkers, and therapeutic potentials.Frontiers in immunology · 2026Review
- Erratum to "Integrated Single-Step Terahertz Metasensing for Simultaneous Detection Based on Exosomal Membrane Proteins Enables Pathological Typing of Gastric Cancer".Research (Washington, D.C.) · 2026Article
- Synergistic terahertz platforms for precision oncology.Theranostics · 2026Review
- Topological and Reconfigurable Terahertz Metadevices.Research (Washington, D.C.) · 2025Review
- Advances in Terahertz Biophysics and Chemistry.Research (Washington, D.C.) · 2025Review
- Electronic Structure Tailored Covalent Organic Frameworks for Synergistic Adsorptive-Photocatalytic Gold Recovery from Complex Electronic Waste.Research (Washington, D.C.) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes (Exos) are emerging as noninvasive biomarkers for diagnosis and progression monitoring of gastric cancer (GC). However, the heterogeneity discrimination and ultrasensitive quantification of Exos presents a considerable analytical challenge, thereby impeding severely their clinical application. Herein, we propose an integrated terahertz metasensing platform for the discrimination of Exos in distinct subtypes of GC in a single step-through the simultaneous evaluation of the category and richness level of Exos membrane proteins. Characterized by dual-sided independent sensing capabilities with enhanced sensitivity (169 and 325 GHz per refractive index unit, respectively), the metasensor functionalized with antibodies simultaneously reflects the content of 2 membrane proteins in the terahertz spectral response. Our approach concurrently completes accurate differentiation and precise quantification of GC-subtype Exos by integrating dual-sided sensing information in merely a single assay. The dual-sided sensing design enhances the reliability of detection results. Moreover, combined with the signal amplification of gold nanoparticles, the platform experimentally demonstrates a superior dynamic response to Exos concentrations spanning from 1 × 10
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.